Two individuals have pleaded guilty in separate cases to importing and selling $7 million worth of unapproved oncology drugs to doctors in the U.S., shedding light on the perils of doctors buying foreign-made drugs and thinking they are getting equal quality at lower prices.
The closed Novartis consumer products plant in Lincoln, NE, that has besmirched the drug giant's reputation and frustrated CEO Joseph Jimenez has bitten the company again.
Johnson & Johnson ($JNJ) and Novartis ($NVS) are the latest pharma companies to feel the ire of EU antitrust regulators. European Commission officials have accused the two drugmakers of delaying a generic version of the painkiller fentanyl--and violating competition laws in the process.
The Facility of the Year Awards recognizes winners from the U.S., Ireland, the U.K. and Switzerland, including three vaccine facilities.
Novartis and its cancer drug Gleevec had one of those days that starts off not looking so good and then something comes along to turn things around.
With a new chairman selected to take the helm of Novartis ($NVS), lots of folks are wondering what is in store for the Swiss drugmaker. Not so fast, CEO Joe Jimenez said this week.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
With a new chairman selected to take the helm of Novartis, lots of folks are wondering what is in store for the Swiss drugmaker. Not so fast, CEO Joe Jimenez said this week.
Watson Pharmaceuticals is no more. The generic drug company has officially taken the name of its most recent acquisition target, Actavis, thinking it has better brand recognition in the markets where it intends to expand.
Novartis may be looking at another trial of its troubled blood pressure drug Tekturna. This would not be a clinical trial, however, but more of the civil or criminal kind.